Press Release Details

Cerus Announces Rhode Island Blood Center Enters into Agreement for the Use of INTERCEPT Platelets and Plasma

December, 23 2015

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that Rhode Island Blood Center (RIBC) has signed a purchase agreement for the INTERCEPT Blood System for platelets and plasma. Rhode Island Blood Center is the primary supplier of blood products to hospitals in Rhode Island, and also services hospitals in nearby Massachusetts and Connecticut. RIBC distributes approximately 12,500 platelet and 42,000 plasma units annually.

“Continuing to layer on screening tests to detect emerging pathogens that pose a risk to patients puts an economic strain on blood centers. We have experienced this first hand with babesiosis, a serious tickborne disease common in Rhode Island,” said Lawrence Smith, President and CEO of the Rhode Island Blood Center. “The opportunity to proactively decrease the risk of transfusion-transmitted diseases made implementing INTERCEPT a priority to continue to fulfill our mission of providing a safe, plentiful and cost-effective blood supply.”

The Rhode Island Blood Center was founded by the hospitals in Rhode Island in 1979 to develop a more efficient system of collecting, testing, and distributing blood products. It has established itself among the leading blood collection agencies nationally, and has grown to a full-service regional blood center, providing testing, collections, a marrow program, and in-hospital therapeutic treatment program for patients. RIBC is a member of Blood Centers of America, a member-owned organization comprised of independent blood centers throughout North America.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for more information about Cerus.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Cerus Corporation Contacts:

Stacey Leanos - Associate Director, Investor & Public Relations

Lainie Corten - Vice President, Global Marketing & Investor Relations

(925) 288- 6137

ir@cerus.com

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600